This potential approval is a significant milestone, positioning Cytokinetics to expand its ... as a leading muscle-focused biopharmaceutical entity, underscoring its commitment to innovation ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq ... products across three indications and ten novel molecular entities (NMEs) in our pipeline. Ignition: Achieve broad access ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq ... Innovation: Advance two approved products across three indications and ten novel molecular entities (NMEs) in our pipeline. Ignition: ...

The National Law Review is a free-to-use, no-log-in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only.

Companies, including healthcare entities, are responsible for complying with new and existing California laws and must take full accountability for their actions, decisions, and products.” ...

This is Film room, where we’ll break down the whirlwind of legal and regulatory activity in college athletics. The ongoing collision between the courts and college athletics can be hard to follow.

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Cytokinetics is on track to submit a New Drug Application (NDA) for aficamten in obstructive HCM (oHCM) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. This timeline ...

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its ...